RSV (Respiratory Syncytial Virus)
17 Sept 2026 · 7 min read

On this page14 sections
Respiratory Syncytial Virus (RSV) is a highly contagious, common winter virus that causes standard coughs and colds. While nearly all children contract RSV by age 2, it is the primary cause of pneumonia and bronchiolitis in infants. Most healthy individuals recover fully within 2 to 3 weeks without medical intervention, but the virus can cause severe, life-threatening complications in specific vulnerable groups.
Emergency Action Required
Call 999 or 112, or go to the nearest Emergency Department immediately if an infant, child, or high-risk adult exhibits any of the following critical symptoms:
Visible difficulty breathing (nostrils flaring, chest or ribs sucking inwards during breaths).
Lips or tongue turning blue or pale.
Inability to wake up or stay awake.
Severe breathing patterns (breathing faster than 60 breaths per minute, or pauses in breathing lasting over 10 seconds).
A pale, sweaty appearance.
Infants: A completely dry nappy for 12 hours or longer.
High-Risk Groups: Any RSV symptoms present in an individual with pre-existing heart/lung disease or a severely weakened immune system.
Urgent Medical Advice
Seek immediate medical care at a GP clinic or Emergency Department if a child has RSV symptoms and fits any of these categories:
Born prematurely (before 37 weeks gestation).
Under 2 months of age.
Diagnosed with chronic heart or lung disease, or an immune deficiency.
High-Risk Groups
RSV carries a significantly higher risk of severe illness or hospitalization for:
Infants under 1 year old and children aged 1 to 4.
Adults aged 65 and older.
Individuals of any age with weakened immune systems or underlying heart and lung conditions.
Note: There is no home test for RSV; confirmation usually occurs via hospital testing if a patient requires admission.
Symptom Progression
Symptoms typically surface in gradual stages rather than all at once:
Initial Stage (Cold-like): Coughing, wheezing, runny nose, sore throat, fever (38°C or higher), and a decreased appetite.
Advanced Stage (Days 4–5): Babies and young children may develop bronchiolitis. Symptoms peak for 3 to 4 days with rapid breathing, worsening wheeze, extreme lethargy, and fewer wet nappies. Full recovery usually takes 10 to 14 days.
Note: A lingering post-viral cough can last for weeks. This is normal and does not require antibiotics, as antibiotics do not treat viruses.
Prevention and Immunisation
RSV spreads rapidly via airborne droplets from coughs and sneezes. Protect vulnerable individuals with these control measures:
Infant Immunisation: A seasonal RSV immunisation is available from September to February for babies under 6 months old to provide vital winter protection.
Hygiene Habits: Wash hands frequently, always use tissues for coughs and sneezes, and discard them immediately.
The "Dab" Technique: Teach older children to drop their face into the crook of their bent elbow when sneezing (resembling the "dab" dance move) if a tissue is unavailable.
Contact Restrictions: Do not share cups, utensils, or water bottles. Avoid close contact with high-risk individuals if you or your child feel unwell.
Home Care and Management Strategies
Do's | Don'ts |
|---|---|
Keep sick children home from school, childcare, and social activities. | Do not expose children to tobacco smoke, which severely worsens RSV respiratory distress. |
Offer frequent, smaller milk feeds if a baby is struggling to feed normally. | Do not force large feeds or large fluid volumes all at once. |
Keep the child upright as much as possible to ease breathing and feeding. | Do not overheat the house, as dry, hot air aggravates inflamed airways. |
Provide extra water or clear juices to prevent dehydration. | Do not ignore changes in feeding; consult a doctor if intake drops by half. |
When to Contact a GP (Non-Emergency)
Consult your GP if you are worried about your child's symptoms or notice any of the following:
The child has fewer than 3 to 4 wet nappies in 24 hours (or a 12-hour dry spell).
An infant refuses to feed, lacks the energy to breastfeed, or becomes too breathless to latch.
A fever of 38°C or higher does not settle with over-the-counter medication.
The child appears unusually short of breath, lethargic, or persistently irritable.
RSV Immunisation for Babies
Respiratory Syncytial Virus (RSV) is a common virus causing chest infections in both children and adults. The risk of severe infection is highest in young infants, particularly those born during the RSV season (September to February in Ireland), where 1 in 2 babies contracts the virus. The RSV immunisation uses Nirsevimab, a long-acting antibody injection that provides immediate protection for 5 months through the autumn and winter. Unlike a traditional vaccine that triggers the body to create its own defenses, Nirsevimab delivers protective antibodies directly into the baby's system.
Key Benefits of the Immunisation
Reduces the risk of a baby becoming seriously ill with RSV.
Lowers the probability of developing lower respiratory tract infections.
Prevents over 80% of RSV-related hospitalisations.
Decreases the likelihood of overnight hospital stays or intensive care admissions.
Eligibility Criteria
Free RSV immunisation is offered to the following cohorts:
Infants born during the current season: Babies born between 1 September 2026 and 28 February 2027.
Infants born just before the season: Babies born between 1 March 2026 and 31 August 2026.
High-risk children under 24 months: Infants born prematurely (before 30 weeks of pregnancy) or those with chronic medical conditions affecting the heart, lungs, or immune system.
Where and How to Access the Service
Patient Group | Administration Location | Action Required |
|---|---|---|
Born Sep 2026 – Feb 2027 | Maternity Hospital | Administered shortly after birth; home-birth parents must arrange a hospital visit through their midwife or obstetrician. |
Born Mar 2026 – Aug 2026 | GP Clinic | Parents must book an appointment directly with their GP practice early in the season. |
High-Risk (Under 24 Months) | HSE Vaccination Team | Parents must consult their paediatrician for a direct referral to the HSE vaccination team. |
Administration and Co-administration
Nirsevimab is given as a single injection into the thigh muscle.
Only one dose is required to provide comprehensive protection through the child's first winter.
It does not interfere with other medical treatments or childhood immunisations, and it can be safely administered at the same time as routine childhood vaccines.
If a baby is actively unwell, the doctor or midwife may temporarily delay the injection until they recover.
Side Effects and Contraindications
Most babies experience no side effects. Fewer than 1 in 100 infants experience mild, temporary symptoms, including:
Redness or swelling at the injection site.
A low-grade fever.
A mild skin rash.
Safety Note: Serious allergic reactions are exceptionally rare. To ensure safety, infants are monitored by medical staff for 15 minutes immediately following the injection. Parents or doctors can report unexpected side effects directly to the Health Products Regulatory Authority (HPRA).
Who Cannot Receive Nirsevimab:
An infant should not receive this immunisation if they have a known severe allergic reaction to any ingredient in the Nirsevimab injection, or if they have previously had a serious hypersensitivity reaction to Nirsevimab or the related drug palivizumab. Additional safety details can be verified via the European Medicines Agency (EMA).
Disclaimer
The information provided here is for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional or your GP for specific medical concerns, diagnoses, or health advice. Never disregard professional medical advice or delay seeking it because of information you have read here.
